Report Regarding the Managements' and Closely Related Parties' Transactions With...

Report Regarding the Managements' and Closely Related Parties' Transactions
With Securities in Exiqon A/S

VEDBAEK, Denmark, September 2 /PRNewswire-FirstCall/ -- Pursuant to
section 28a of the Danish Securities Trading Act, Exiqon A/S is required to
publish the managements' and their closely related parties' transactions with
shares and related securities in Exiqon A/S.
Name: Per Wold-Olsen
Reason for reporting: Member of Exiqon's Board
of Directors

Security Code (ISIN-kode): DK0060077758

Name of the securities: Share

Type of transaction: Buy

Date of trade 2 September 2008

Place of transaction: OMX Nordic Exchange
Copenhagen

Traded securities (no.): 10.000

Market value in DKK of traded 270.000,00
securities:

About Exiqon
Exiqon is dedicated to personalizing the treatment selection for cancer
patients. Our goal is to optimise the use of existing medicine and avoid
unnecessary and non-effective treatment. We aim to achieve this through
improved diagnosis: by using diagnostic tests that analyses the genetic
profile of each patient's tumour, we can help optimise the treatment
selection for the individual patients. Exiqon is uniquely positioned to
develop such new diagnostic tests, and we possess the necessary technology.
The technology is referred to as LNA(TM). Using this technology, over a
period of only four years Exiqon has been able to establish a position for
itself as one of the market's leading providers of research products for gene
expression analysis.
Our research products are used by university scientists and in the
pharmaceutical industry around the world to make groundbreaking discoveries
about the correlation between gene activity and the development of cancer and
other disorders such as neurological disorders and metabolic diseases.
We are currently developing our new molecular diagnostic products, and
the first new product based on the LNA(TM) technology is scheduled for
launched by the end of 2008. A number of new products will follow in the
years ahead. Exiqon already has a significant market presence through its
existing diagnostic product sales to hospitals in the USA. Through Oncotech,
Exiqon markets diagnostic products that enable doctors to test whether their
patients are resistant to one or more of the chemotherapies offered to treat
these patients and helps them select an efficacious treatment. Oncotech is
the market leader when it comes to selling such diagnostic tests based on an
analysis of fresh tumour tissue. Exiqon plans to use Oncotech's leading
market position to sell our new molecular diagnostic products based on the
LNA(TM) technology.
Exiqon has more than 200 employees and is listed on the NASDAQ OMX in
Copenhagen and categorised as a biotech company (Small Cap+).
Disclaimer
Forward-looking statements:
This announcement contains forward-looking statements regarding Exiqon's
potential future development and financial performance and other statements
which are not historical facts. Such statements are made on the basis of
assumptions and expectations which, to the best of Exiqon's knowledge, are
reasonable and well-founded at this time, but which may prove to be
erroneous. Exiqon's operations are characterized by the fact that its actual
results may deviate significantly from that described herein as anticipated,
believed, estimated or expected.
SOURCE Exiqon A/S

Additional information: CEO Lars Kongsbak, tlf. +45-45-66-08-88, or
+45-40-90-21-01; CFO Hans Henrik Chrois Christensen tlf. +45-45-66-08-88, or
+45-40-90-21-31